DinarelloC.A. (1996). Thermoregulation and the pathogenesis of fever. Infectious Disease Clinics of North America10, 433–499.
3.
AlheimK., & BartfaiT. (1998). The interleukin-1 system: receptors, ligands, and ICE in the brain and their involvement in the fever response. Annals of the New York Academy of Sciences840, 51–58.
FreudenbergM.A., & GalanosC. (1990). Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. International Reviews of Immunology6, 207–221.
6.
HolstO., UlmerA.J., BradeH., FladH.D., & RietschelE.T. (1996). Biochemistry and cell biology of bacterial endotoxins. FEMS Immunology and Medical Microbiology16, 83–104.
7.
RietschelE.T., BradeL., HolstO., KulshinV.A., LindnerB., MoranA.P., SchadeU.F., ZähringerU., & BradeH. (1990). Molecular structure of bacterial endotoxin in relation to bioactivity. In Cellular and Molecular Aspects of Endotoxin Reactions (ed. NowotnyA., SpitzerJ.J., & ZieglerE. J.), pp. 15–32. Amsterdam, The Netherlands, Elsevier.
8.
RietschelE.T., KirikaeT., SchadeU.F., MamatU., SchmidtG., LoppnowH., UlmerA.J., ZähringerU., SeydelU., & Di PadovaF. (1994). Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB Journal8, 217–225.
9.
RietschelE.T., BradeH., HolstO., BradeL., Muller-LoenniesS., MamatU., ZähringerU., BeckmannF., SeydelU., BrandenburgK., UlmerA.J., MatternT., HeineH., SchletterJ., LoppnowH., SchonbeckU., FladH.D., HauschildtS., SchadeU.F., Di PadovaF., KusumotoS., & SchumannR.R. (1996). Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Current Topics in Microbiology and Immunology216, 39–81.
10.
DerijkR.H., StrijbosP.J., van RooijenN., RothwellN.J., & BerkenboschF. (1993). Fever and thermogenesis in response to bacterial endotoxin involve macrophage-dependent mechanisms in rats. American Journal of Physiology265, R1179–R1183.
11.
KlugerM.J. (1991). Fever: role of pyrogens and cryogens. Physiological Reviews71, 93–127.
12.
SaperC.B., & BrederC.D. (1992). Endogenous pyrogens in the CNS: role in the febrile response. Progress in Brain Research93, 419–428
13.
MoltzH. (1993). Fever: causes and consequences. Neuroscience and Biobehavioral Reviews17, 237–269.
LuheshiG., & RothwellN. (1996). Cytokines and fever. International Archives of Allergy and Immunology109, 301–307.
16.
LuheshiG.N. (1998). Cytokines and fever. Mechanisms and sites of action. Annals of the New York Academy of Sciences856, 83–89.
17.
MackowiakP.A. (1998). Concepts of fever. Archives of Internal Medicine158, 1870–1881.
18.
ZetterstromM., Sundgren-AnderssonA.K., OstlundP., & BartfaiT. (1998). Delineation of the proinflammatory cytokine cascade in fever induction. Annals of the New York Academy of Sciences856, 48–52.
19.
DinarelloC.A. (1984). Interleukin-1. Reviews of Infectious Diseases6, 51–95.
20.
EndresS., van der MeerJ.W., & DinarelloC.A. (1987). Interleukin-1 in the pathogenesis of fever. European Journal of Clinical Investigation17, 469–474.
21.
DinarelloC.A., CannonJ.G., MancillaJ., BishaiI., LeesJ., & CoceaniF. (1991). Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Research562, 199–206.
22.
ChaiZ., GattiS., ToniattiC., PoliV., & BartfaiT. (1996). Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. Journal of Experimental Medicine183, 311–316.
23.
DinarelloC.A., CannonJ.G., WolffS.M., BernheimH.A., BeutlerB., CeramiA., FigariI.S., PalladinoM.A.Jr., & O'ConnorJ.V. (1986). Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. Journal of Experimental Medicine163, 1433–1450.
24.
KawasakiH., MoriyamaM., OhtaniY., NaitohM., TanakaA., & NariuchiH. (1989). Analysis of endotoxin fever in rabbits by using a monoclonal antibody to tumor necrosis factor (cachectin). Infection and Immunity57, 3131–3135.
25.
RedfordJ., BishaiI., & CoceaniF. (1995). Pyrogen–prostaglandin coupling in the pathogenesis of fever: evidence against a role for nitric oxide. Canadian Journal of Physiology and Pharmacology73, 1466–1474.
26.
OkaK., OkaT., & HoriT. (1998). PGE 2 receptor subtype EP1 antagonist may inhibit central interleukin-1β-induced fever in rats. American Journal of Physiology275, R1762–R1765.
27.
van DijckP., & van de VoordeH. (1977). Factors affecting pyrogen testing in rabbits. Developments in Biological Standardisation34, 57–63.
28.
El-KhalikA.F., & BenolielD.M. (1982). Effects of weight and sex of rabbits on the results of the testing of chorionic gonadotrophin injection according to the European Pharmacopoeia. The Journal of Pharmacy and Pharmacology34, 209–210.
29.
GreismanS.E., & HornickR.B. (1969). Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proceedings of the Society of Experimental Biology and Medicine131, 1154–1158.
30.
BonenbergerJ., DiekmannW., FennrichS., FischerM., FriedrichA., HansperM., HartungT., JahnkeM., LöwerJ., MontagT., PetriE., SonntagH-G., WeigandM., WendelA., & ZuckerB. (2000). Pyrogentestung mit Vollblut—Zusammenfassung eines Status-Workshops am Paul-Ehrlich-Institut, Langen, am 22.11.1999. Bundesgesundheitsblatt—Gesundheitsforschung— Gesundheitsschutz7, 525–533.
31.
BellentaniL. (1982). Cyclic and chronobiological considerations when employing the rabbit fever test. Progress in Clinical and Biological Research93, 329–342.
32.
HullD., McIntyreJ., & VinterJ. (1993). Age-related changes in endotoxin sensitivity and the febrile response of newborn rabbits. Biology of the Neonate63, 370–379.
33.
CooperJ.F., HochsteinH.D., & SeligmannE.B.Jr (1972). The Limulus test for endotoxin (pyrogen) in radiopharmaceuticals and biologicals. Bulletin of the Parenteral Drug Association26, 155–162.
34.
CooperJ.F. (1979). Acceptance of the Limulus test as an alternative pyrogen test for radiopharmaceutical and intrathecal drugs. Progress in Clinical and Biological Research29, 345–352.
35.
CohenY., BahriF., BruneauJ., DubuisM., DubuisN., MerlinL., MichaudT., & PeyssonS. (1986). Detection of endotoxins in radiopharmaceutical preparations. III. Limulus test assessment using radiopharmaceutical preparations; correlation with the rabbit pyrogen test. International Journal of Nuclear Medicine and Biology, Elmsford, NY12, 477–481.
36.
BoothC. (1986). The Limulus amoebocyte lysate (LAL) assay: a replacement for the rabbit pyrogen test. Developments in Biological Standardisation64, 271–275.
37.
FlintO. (1994). A timetable for replacing, reducing and refining animal use with the help of in vitro tests: the Limulus amebocyte lysate test (LAL) as an example. In Alternatives to Animal Testing: New Ways in the Biomedical Sciences, Trends and Progress (ed. ReinhardtC.A.), pp. 27–43. Weinheim, Germany: Verlag Chemie.
38.
LiebschM. (1995). Die Geschichte der Validierung des LAL-Tests. ALTEX12, 76–80.
39.
GardiA., & ArpagausG.R. (1980). Improved microtechnique for endotoxin assay by the Limulus amebocyte lysate test. Analytical Biochemistry109, 382–385.
40.
FribergerP. (1985). The design of a reliable endotoxin test. Progress in Clinical and Biological Research189, 139–149.
41.
McCulloughK.Z., & Weidner-LoevenC. (1992). Variability in the LAL test: comparison of three kinetic methods for the testing of pharmaceutical products. Journal of Parenteral Science and Technology46, 69–72.
42.
MeiselJ. (1995). Pyrogenbestimmung: Ein Vergleich verschiedener Methoden. ALTEX12, 89–92.
43.
KrügerD. (1981). Der Pyrogennachweis mittels des Limulustests — Methoden, Ergebnisse, Möglichkeiten und Grenzen eines In-vitro-Tests. Die Pharmazeutische Industrie43, 1–8
44.
PearsonF.C., WearyM.E., SargentH.E., NovitskyT.J., LinH., LindsayG., BerzofskyR.N., LaneA.L., WilsonJ.D., CooperJ.F., HelmeE.J., TwohyC.W., BaschH.I., RechM., SladeJ.W., & WinegarM.P. (1985). Comparison of several control standard endotoxins to the National Reference Standard Endotoxin: an HIMA collaborative study. Applied Environmental Microbiology50, 91–93.
45.
PooleS., & MussettM.V. (1989). The International Standard for Endotoxin: evaluation in an international collaborative study. Journal of Biological Standardisation17, 161–171.
46.
PooleS., DawsonP., & Gaines DasR.E. (1997). Second International Standard for Endotoxin: calibration in an international collaborative study. Journal of Endotoxin Research4, 221–231.
47.
Laude-SharpM., Haeffner-CavaillonN., CaroffM., LantreibecqF., PusineriC., & KazatchkineM.D. (1990). Dissociation between the interleukin 1-inducing capacity and Limulus reactivity of lipopolysaccharides from Gram-negative bacteria. Cytokine2, 253–258.
48.
FennrichS., FischerM., HartungT., LexaP., Montag-LessingT., SonntagH-G., WeigandtM., & WendelA. (1998). Entwicklung und Evaluierung eines Pyrogentests mit menschlichem Blut. ALTEX15, 123–128.
49.
KundsinR.B., & WalterC.W. (1980). Detection of endotoxin on sterile catheters used for cardiac catheterization. Journal of Clinical Microbiology11, 209–212.
50.
MadisonV., GreveT., AveryB., & WambergT. (1991). The effect of endotoxin-contaminated medium on in vitro fertilization and development of bovine oocytes matured in vitro. Reproduction Fertility and Development31, 159–165.
SarantilaR., KotimaaM., KalliokoskiP., & PonniJ. (1989). Endotoxin detection and quantification in airborne dust. Pharmeuropa1, 20.
53.
TaktakY.S., SelkirkS., BristowA.F., CarpenterA., BallC., RaffertyB., & PooleS. (1991). Assay of pyrogens by interleukin-6 release from monocytic cell lines. The Journal of Pharmacy and Pharmacology43, 578.
54.
EperonS., & JungiT.W. (1996). The use of human monocytoid lines as indicators of endotoxin. Journal of Immunological Methods194, 121–129.
55.
EperonS., DeGrooteD., Werner-FelmayerG., & JungiT.W. (1997). Human monocytoid cell lines as indicators of endotoxin: comparison with rabbit pyrogen and Limulus amoebocyte lysate assay. Journal of Immunological Methods207, 135–145.
56.
PeterbauerA., WernerE.R., & Werner-FelmayerG. (1999). Weiterentwicklung eines Zellkulturmodells zum Nachweis bakterieller Pyrogene. ALTEX16, 3–8.
57.
PeterbauerA., WernerE.R., & Werner-FelmayerG. (1999). Neopterin and nitrite in supernatants from interferon-gamma-treated monocytoid cell lines: a tool to identify bacterial pyrogens. Pteridines10, 112–118.
58.
PeterbauerA., EperonS., JungiT.W., WernerE.R., & Werner-FelmayerG. (2000). Interferongamma-primed monocytoid cell lines: optimizing their use for in vitro detection of bacterial pyrogens. Journal of Immunological Methods233, 67–76.
59.
Werner-FelmayerG., Baier-BitterlichA.F., FuchsD., HausenA., MurrC., ReibneggerG., WernerE.R., & WachterH. (1995). Detection of bacterial pyrogens on the basis of their effects on gamma interferon-mediated formation of neopterin or nitrite in cultured monocyte cell lines. Clinical and Diagnostic Laboratory Immunology2, 307–313.
60.
DuffG.W., & AtkinsE. (1982). The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with Limulus amebocyte lysate gelation. Journal of Immunological Methods52, 323–331.
61.
DinarelloC.A., O'ConnorJ.V., LoPresteG., & SwiftR.L. (1984). Human leukocytic pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli.Journal of Clinical Microbiology20, 23–329.
62.
PooleS., ThorpeR., MeagerA., HubbardA.R., & GearingA.J. (1988). Detection of pyrogen by cytokine release. Lancet1, 130.
63.
PooleS., ThorpeR., MeagerA., & GearingA.J. (1988). Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes. Developments in Biological Standardisation69, 121–123.
64.
ChiaJ.K., & McManusE.J. (1990). In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrobial Agents and Chemotherapy34, 906–908.
65.
Wind HansenE., & Dencker ChristensenJ. (1990). Comparison of cultured human mononuclear cells, Limulus amebocyte lysate and rabbits in the detection of pyrogens. Journal of Clinical Pharmacology and Therapeutics15, 425–433.
66.
MorinM., SchindlerR., WakabayashiG., DaumyG., DinarelloC.A., & GelfandJ.A. (1991). Picogram concentrations of endotoxin stimulate synthesis of IL-1 beta and TNF alpha by human peripheral blood mononuclear cells exposed to recombinant human C5a. European Cytokine Network2, 27–30.
67.
HartungT., & WendelA. (1995). Die Erfassung von Pyrogenen in einem humanen Vollblutmodell. ALTEX12, 70–75.
68.
HartungT., & WendelA. (1996). Eine Methode unter Verwendung von menschlichem Vollblut zum Ersatz des Pyrogentests am Kaninchen. In Forschung ohne Tierversuche (ed. SchöfflH., SpielmannH., TritthartH.A., CusslerK., GoetschelA.F., GruberF.P., & ReinhardtC.A.), pp. 34–39. Vienna, Austria: Springer-Verlag.
69.
HartungT., & WendelA. (1996). Detection of pyrogens using human whole blood. In Vitro Toxicology9, 353–359.
70.
PoolE.J., JohaarG., JamesS., PetersenI., & BouicP. (1998). The detection of pyrogens in blood products using an ex vivo whole blood culture assay. Journal of Immunoassay19, 95–111.
71.
FennrichS., BertholdS., WeigandtM., LexaP., SonntagH-G., HartungT., & WendelA. (1999). Pyrogentestung mit humanem Blut. Der Tierschutzbeauftragte2, 102–107.
72.
FennrichS., FischerM., HartungT., LexaP., Montag-LessingT., SonntagH.G., WeigandtM., & WendelA. (1999). Detection of endotoxins and other pyrogens using human whole blood. Developments in Biological Standardisation101, 31–139.
73.
FennrichS., WendelA., & HartungT. (1999). New applications of the human whole blood pyrogen assay (PyroCheck). ALTEX16, 146–149.
74.
JahnkeM., WeigandM., & SonntagH-G. (2000). Comparative testing for pyrogens in parenteral drugs using the human whole blood pyrogen test, the rabbit in vivo pyrogen test and the LAL test. European Journal of Parenteral Sciences5, 39–44.
75.
HartungT., FennrichS., FischerM., Montag-LessingT., & WendelA. (2000). Prevalidation of an alternative to the rabbit pyrogen test based on human whole blood. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. BallsM., van ZellerA-M., & HalderM.E.), pp. 991–999. Amsterdam, The Netherlands: Elsevier.
76.
MurphyP.A. (1991). Exogenous pyrogens. In Fever: Basic Mechanism and Management (ed. MackowiakP.), pp. 49–58. New York, USA: Raven Press.
77.
HitchcockP.J., & MorrisonD.C. (1984). The protein components of bacterial endotoxins. In Chemistry of Endotoxin (ed. RietschelE.T.), pp. 339–375. Amsterdam, The Netherlands: Elsevier.
78.
DinarelloC.A., ElinR.J., ChedidL., & WolffS.M. (1978). The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. Journal of Infectious Diseases138, 760–767.
79.
JohannsenL., WeckeJ., ObalF.Jr., & KruegerJ.M. (1991). Macrophages produce somnogenic and pyrogenic muramyl peptides during digestion of staphylococci. American Journal of Physiology260, R126–R133.
80.
BenzR. (1988). Structure and function of porins from Gram-negative bacteria. Annual Review of Microbiology42, 359–393.
81.
GaldieroF., TufanoM.A., GaldieroM., MasielloS., & Di RosaM. (1990). Inflammatory effects of Salmonella typhimurium porins. Infection and Immunity58, 3183–3186.
82.
GaldieroF., SommeseL., ScarfoglieroP., & GaldieroM. (1994). Biological activities: lethality, Schwartzman reaction and pyrogenicity of Salmonella typhimurium porins. Microbial Pathogenesis16, 111–119.
83.
FumarolaD., MunnoI., MarcuccioC., & MiragliottaG. (1986). Endotoxin-like activity associated with Lyme disease Borrelia.Zentralblatt für Bakteriologie, Mikrobiologie und Hygiene263, 142–145.
84.
ThomsenA., & LoppnowH. (1995). Cytokine production by mononuclear cells following stimulation with a peptide-containing, endotoxin-free Escherichia coli extract. Arzneimittelforschung45, 657–661.
85.
ElinR.J., & UtterA.E. (1980). Positive Limulus amoebocyte lysate reactions with polyriboinosinic acid x polyribocytidylic acid. Journal of Clinical Microbiology12, 502–505.
86.
WonS.J., & LinM.T. (1993). Endogenous pyrogen formation by human blood monocytes stimulated by polyriboinosinic acid x polyribocytidylic acid. Experientia49, 157–159.
87.
CowderyJ.S., ChaceJ.H., YiA.K., & KriegA.M. (1996). Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. Journal of Immunology156, 4570–4575.
WexlerH., & OppenheimJ.D. (1979). Isolation, characterization, and biological properties of an endotoxin-like material from the Gram-positive organism Listeria monocytogenes.Infection and Immunity23, 845–857.
90.
VallejoJ.G., BakerC.J., & EdwardsM.S. (1996). Roles of the bacterial cell wall and capsule in induction of tumor necrosis factor alpha by type III group B streptococci. Infection and Immunity64, 5042–5046.
91.
ToienO., & MercerJ.B. (1996). Thermosensitivity is reduced during fever induced by Staphylococcus aureus cell walls in rabbits. Pflugers Archiv European Journal of Physiology432, 66–74.
92.
HuangW.T., LinM.T., & WonS.J. (1997). Staphylococcal enterotoxin A-induced fever is associated with increased circulating levels of cytokines in rabbits. Infection and Immunity65, 2656–2662.
93.
HuangW.T., LinM.T., & WonS.J. (1997). Mechanisms and sites of pyrogenic action exerted by staphylococcal enterotoxin A in rabbits. Neuroscience Letters236, 53–56.
94.
RoggianiM., StoehrJ.A., LeonardB.A., & SchlievertP.M. (1997). Analysis of toxicity of streptococcal pyrogenic exotoxin A mutants. Infection and Immunity65, 2868–2875.
95.
HackettS.P., & StevensD.L. (1992). Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. The Journal of Infectious Diseases165, 879–885.
96.
FitzgeraldD., & PastanI. (1993). Pseudomonas exotoxin and recombinant immunotoxins derived from it. Annals of the New York Academy of Sciences685, 740–745.
97.
BhakdiS., GrimmingerF., SuttorpN., WalmrathD., & SeegerW. (1994). Proteinaceous bacterial toxins and pathogenesis of sepsis syndrome and septic shock: the unknown connection. Medical Microbiology and Immunology, Berlin183, 119–144 [published erratum appears in Medical Microbiology and Immunology, Berlin 183, 343–344].
98.
HouldsworthS., AndrewP.W., & MitchellT.J. (1994). Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infection and Immunity62, 1501–1503.
99.
MuraiT., NakagawaY., & OgawaY. (1996). Potentiation of lethal endotoxin shock by streptococcal pyrogenic exotoxin in rabbits: possible relevance of hyperreactivity of macrophages to endotoxin. FEMS Immunology and Medical Microbiology13, 269–272.
100.
CarsonL.A., BlandL.A., CusickL.B., FaveroM.S., BolanG.A., ReingoldA.L., & GoodR.C. (1988). Prevalence of nontuberculous mycobacteria in water supplies of hemodialysis centers. Applied Environmental Microbiology54, 3122–3125.
101.
RawadiG., & Roman-RomanS. (1996). Mycoplasma membrane lipoproteins induced proinflammatory cytokines by a mechanism distinct from that of lipopolysaccharide. Infection and Immunity64, 637.
102.
BarwickV.S., WootenM.H., BradfieldJ.F., & MyersR.D. (1994). Fever of unknown origin: due to C. albicans or other fungi acting on the hypothalamus?Brain Research635, 1–8.
103.
BateC.A., TaverneJ., & PlayfairJ.H. (1989). Soluble malarial antigens are toxic and induce the production of tumour necrosis factor in vivo.Immunology66, 600–605.
104.
BarryD.W., MaynerR.E., HochsteinH.D., DunlapR.C., RastogiS.C., HannahJ.E., BlackburnR.J., SullivanJ.L., & GeretyR.J. (1976). Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. American Journal of Epidemiology104, 47–59.
105.
JakemanK.J., BirdC.R., ThorpeR., SmithH., & SweetC. (1991). Nature of the endogenous pyrogen (EP) induced by influenza viruses: lack of correlation between EP levels and content of the known pyrogenic cytokines, interleukin 1, interleukin 6 and tumour necrosis factor. Journal of General Virology72, 705–709.
106.
GongJ.H., SprengerH., HinderF., BenderA., SchmidtA., HorchS., NainM., & GemsaD. (1991). Influenza A virus infection of macrophages: enhanced tumor necrosis factor-alpha (TNF-alpha) gene expression and lipopolysaccharide-triggered TNF-alpha release. Journal of Immunology147, 3507–3513.
107.
BeckerS., QuayJ., & SoukupJ. (1991). Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. Journal of Immunology147, 4307–4312.
108.
AlluwaimiA.M., SmithH., & SweetC. (1994). Role of surface glycoproteins in influenza virus pyrogenicity. Journal of General Virology75, 2835–2840.
109.
ChangD.M., & ShaioM.F. (1994). Production of interleukin-1 (IL-1) and IL-1 inhibitor by human monocytes exposed to dengue virus. Journal of Infectious Diseases170, 811–817.
110.
KurokawaM., ImakitaM., KumedaC.A., & ShirakiK. (1996). Cascade of fever production in mice infected with influenza virus. Journal of Medical Virology50, 152–158.
111.
PriceG.E., FentonR.J., SmithH., & SweetC. (1997). Are known pyrogenic cytokines responsible for fever in influenza?Journal of Medical Virology52, 336–340.
112.
SopranaE., VigoE., VeraniA., BlomJ., SiccardiA.G., VercelliD., & VialeG. (1994). Antiidiotypic antibodies mimic molecular and functional properties of human IL-1 beta in vitro and in vivo.Lymphokine Cytokine Research13, 325–330
113.
MillerK.M., & AndersonJ.M. (1988). Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers. Journal of Biomedical Material Research22, 713–731.
114.
BeloeilJ.C., EsnaultC., FetizonM., & HenryR. (1980). Synthesis and pyrogenic effect of 3α, 7α-dihydroxy-5β -androstan-17-one and 3α-hydroxy-5β-androstane-7,17-dione. Steroids35, 281–293.
115.
BodelP., & DillardM. (1968). Studies on steroid fever. I. Production of leukocyte pyrogen in vitro by etiocholanolone. Journal of Clinical Investigation47, 107–117.
116.
ColemanM.D. (1995). Dapsone toxicity: some current perspectives. General Pharmacology26, 1461–1467.
117.
HollonT. (2000). Researchers and regulators reflect on first gene therapy death. Nature Medicine6, 6
118.
TsuchidaK., TakemotoY., YamagamiS., EdneyH., NiwaM., TsuchiyaM., KishimotoT., & ShaldonS. (1997). Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and Limulus amebocyte lysate methods. Nephron75, 438–443.
119.
TsuchiyaM., AsahiN., SuzuokiF., AshidaM., & MatsuuraS. (1996). Detection of peptidoglycan and beta-glucan with silkworm larvae plasma test. FEMS Immunological and Medical Microbiology15, 129–134.
120.
SzrederZ. (1997). Do cardiovascular mechanisms participate in thermoregulatory activity of alpha 2-adrenoceptor agonists and antagonists in rabbits?Annals of the New York Academy of Sciences813, 512–525.
121.
GagaloI.T., HacE.E., MatuszekM.T., RekowskiP., KupryszewskiG., & KorolkiewiczK.Z. (1995). Thermoregulatory activity of sodium nitroprusside and arginine vasopressin. General Pharmacology26, 393–397.
122.
GagaloI.T., HacE.E., KorolkiewiczK.Z., MatuszekM.T., & SzrederZ. (1996). Do sodium nitroprusside and L-NAME affect pyrogen fever in rabbits?Acta Physiologica Hungarica84, 289–290.
123.
GagaloI.T., & MatuszekM.T. (1997). The effect of N6-cyclohexyladenosine and 5'-(N-cyclopropyl)carboxamidoadenosine on pyrogen fever in rabbits. Annals of the New York Academy of Sciences813, 353–359.
FlaniganM.J., AcconeQ., & LaburnH.P. (1992). Amitriptyline attenuates the febrile response to a pyrogen in rabbits. Journal of Basic Clinical Physiology and Pharmacology3, 19–32.
126.
CradockJ.C., VishnuvajjalaB.R., ChinT.F., HochsteinH.D., & AckermanS.K. (1986). Uridine-induced hyperthermia in the rabbit. Journal of Pharmacy and Pharmacology38, 226–229.
127.
KleszynskiR.R., HoffmanD., OdenealA., & AldredJ.P. (1982). Apparent influence of adrenocorticotrophic hormone (ACTH) in the USP rabbit pyrogen test and evaluation of LAL as an alternative procedure. Progress in Clinical and Biological Research93, 357–363.
128.
CooperJ.F., WearyM.E., & JordanF.T. (1997). The impact of non-endotoxin LAL-reactive materials on Limulus amebocyte lysate analyses. PDA Journal of Pharmaceutical Science and Technology51, 2–6.
129.
DunerK.I. (1995). The importance of the quality of water in Limulus amebocyte lysate tests. PDA Journal of Pharmaceutical Science and Technology49, 119–121.
130.
HurleyJ.C., TosoliniF.A., & LouisW.J. (1991). Quantitative Limulus lysate assay for endotoxin and the effect of plasma. Journal of Clinical Pathology44, 849–854.
131.
al-KhalifaI.J., NaiduN.V., NallariV.R., & RautH.I. (1989). Effect of some penicillins on the sensitivity of Limulus amoebocyte lysate test. Journal of Pharmacy and Pharmacology41, 127–128.
132.
ElinR.J., & WolffS.M. (1973). Nonspecificity of the Limulus amebocyte lysate test: positive reactions with polynucleotides and proteins. Journal of Infectious Diseases128, 349–352.
133.
IkemuraK., IkegamiK., ShimazuT., YoshiokaT., & SugimotoT. (1989). False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. Journal of Clinical Microbiology27, 1965–1968.
134.
RoslanskyP.F., DawsonM.E., & NovitskyT.J. (1991). Plastics, endotoxins, and the Limulus amebocyte lysate test. Journal of Parenteral Science and Technology45, 83–87.
135.
RossV.C., & BruchC.W. (1982). Endotoxin testing of medical devices with LAL: FDA requirements. Progress in Clinical and Biological Research93, 39–48.
136.
MartinezF., & ColemanJ.W. (1989). The effects of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro.Clinical and Experimental Immunology76, 252–257.
137.
Council of Europe (1997). Parenteral Preparations. In European Pharmacopoeia, 3rd edn, pp. 1765–1767. Strasbourg, France: Council of Europe.
138.
BeckerK.P., DitterB., NimskyC., UrbaschekR., & UrbaschekB. (1988). Endotoxin contents of phytopharmaceuticals: correlation with clinically observed side effects. Deutsche Medizinische Wochenschrift113, 83–87.
139.
ScheerR. (1993). The effect of mistletoe lectins on the Limulus amebocyte lysate test. Arzneimittelforschung43, 795–800.
140.
KnightP.A., & LuckenR.N. (1977). Studies on the toxicity of a variety of human vaccines as measured by laboratory tests. Developments in Biological Standardisation34, 181–187.
141.
TsaiC.M., FraschC.E., RiveraE., & HochsteinH.D. (1989). Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. Journal of Biological Standardisation17, 249–258.
142.
NyergesG., & JaszovszkyI. (1981). Reliability of the rabbit pyrogen test and of the Limulus test in predicting the pyrogenicity of vaccines in man. Acta Microbiologica Academiae Scientiarum Hungaricae28, 235–243.
NovitskyT.J., Schmidt-GengenbachJ., & RemillardJ.F. (1986). Factors affecting recovery of endotoxin adsorbed to container surfaces. Journal of Parenteral Science and Technology40, 284–286.
145.
NelsonS.K., KnoernschildK.L., RobinsonF.G., & SchusterG.S. (1997). Lipopolysaccharide affinity for titanium implant biomaterials. Journal of Prosthetic Dentistry77, 76–82.
146.
MillerA.J., HopkinsS.J., & LuheshiG.N. (1997). Sites of action of IL-1 in the development of fever and cytokine responses to tissue inflammation in the rat. British Journal of Pharmacology120, 1274–1279.
147.
KirkpatrickC.J., WagnerM., KöhlerH., BittingerF., OttoM., & KleinC.L. (1997). The cell and molecular biological approach to biomaterial research: a perspective. Journal of Materials Science: Materials in Medicine8, 131–141.
148.
KirkpatrickC.J., BittingerF., WagnerM., KöhlerH., van KootenT.G., KleinC.L., & OttoM. (1998). Current trends in biocompatibility testing. Proceedings of the Institution of Mechanical Engineers [H]212, 75–84.
149.
DeiningerC. (1998). Vorschlag eines Richtwertes für Endotoxin. Gefahrstoffe — Reinhaltung der Luft1998, 23.
150.
SenkpielK. (1999). Gesundheitliche Gefahren durch biogene Luftschadstoffe. Hygiene und Mikrobiologie24, 45–49.
151.
Descamps-LatschaB., HerbelinA., NguyenA.T., UzanM., & ZingraffJ. (1986). Haemodialysis-membrane-induced phagocyte oxidative metabolism activation and interleukin-1 production. Life Support Systems4, 349–353.
152.
KleinE., PassT., HardingG.B., WrightR., & MillionC. (1990). Microbial and endotoxin contamination in water and dialysate in the central United States. Artificial Organs14, 85–94.
153.
Laude-SharpM., CaroffM., SimardL., PusineriC., KazatchkineM.D., & Haeffner-CavaillonN. (1990). Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney International38, 1089–1094.
154.
DarenkovA.F., YermolenkoV.M., SinyukhinV.N., StetsyukE.A., KochlovA.P., & YarmolinskiJ.S. (1991). Pathophysiological effects of a Limulus amoebocyte-lysate-positive substance during haemodialysis. Nephrology Dialysis Transplantation3, 62–65.
155.
GordonS.M., OettingerC.W., BlandL.A., OliverJ.C., ArduinoM.J., AgueroS.M., McAllisterS.K., FaveroM.S., & JarvisW.R. (1992). Pyrogenic reactions in patients receiving conventional, high-efficiency, or high-flux hemodialysis treatments with bicarbonate dialysate containing high concentrations of bacteria and endotoxin. Journal of the American Society of Nephrology2, 1436–1444.
156.
JacksonB.M., Beck-SagueC.M., BlandL.A., ArduinoM.J., MeyerL., & JarvisW.R. (1994). Outbreak of pyrogenic reactions and Gram-negative bacteria in a hemodialysis center. American Journal of Nephrology14, 85–89.
157.
DinarelloC.A. (1995). Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications?Nephrology Dialysis Transplantation10, 25–28.
158.
LaurenceR.A., & LapierreS.T. (1995). Quality of hemodialysis water: a 7-year multicenter study. American Journal of Kidney Diseases25, 738–750.
159.
ArduinoM.J., BlandL.A., McAllisterS.K., & FaveroM.S. (1995). The effects of endotoxincontaminated dialysate and polysulfone or cellulosic membranes on the release of TNF alpha during simulated dialysis. Artificial Organs19, 880–886.
160.
RudnickJ.R., ArduinoM.J., BlandL.A., CusickL., McAllisterS.K., AgueroS.M., & JarvisW.R. (1995). An outbreak of pyrogenic reactions in chronic hemodialysis patients associated with hemodialyzer reuse. Artificial Organs19, 289–296.
161.
ArvanitidouM., SpaiaS., KatsinasC., PangidisP., ConstantinidisT., KatsouyannopoulosV., & VayonasG. (1998). Microbiological quality of water and dialysate in all haemodialysis centres of Greece. Nephrology Dialysis Transplantation13, 949–954.
162.
Martinez-BermudezA., Rodriguez-de LeceaJ., Soto-EsterasT., Vazquez-EstevezC., & Chena-CaneteC. (1991). Types of microbial contaminants in pharmaceutical raw materials. Revista Latinoamericana di Microbiologia33, 153–157.
163.
MajdeJ.A. (1993). Microbial cell-wall contaminants in peptides: a potential source of physiological artifacts. Peptides14, 629–632.
164.
DonroeA., GablerR., WinterP., ChristiansenG., DeRosaD., HillD., HoggattE., ReaJ., ShannonM., & SimonsI. (1990). Current practices in endotoxin and pyrogen testing in biotechnology. The Quality Assurance/Quality Control Task Group. Journal of Parenteral Science and Technology44, 39–45
165.
BPI (1999). Pharma Daten, pp. 52. Frankfurt, Germany: Bundesverband der Pharmazeutischen Industrie.
166.
ICH (1995). Text on Validations of Analytical Procedures. CPMP/ICH/381/95. Geneva, Switzerland: International Conference on Harmonization.
167.
MunsonT.E. (1982). FDA guideline for validation of the LAL test as an end-product endotoxin test for human and biological drugs. Progress in Clinical and Biological Research93, 25–32.
168.
MunsonT.E. (1987). FDA LAL guideline-update. Progress in Clinical and Biological Research231, 143–147.
169.
FDA (1991). US Food and Drug Administration Guideline on validation of the Limulus amebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products and medical devices. DHHS, Dec. 1987 and Interim Guidance, 1991.Washington, DC, USA: DHHS.
170.
ZarnowK., & SpielmanH. (1998). Möglichkeiten zur Reduzierung oder zum Ersatz von Tierversuchen, die in DIN-Normen vorgeschrieben sind. ALTEX15, 129–140.
171.
Council of Europe (1997). 2.6.8. Pyrogens. In European Pharmacopoeia, 3rd edition, pp. 80–81. Strasbourg, France: Council of Europe.
172.
Council of Europe (2001). 2.6.14. Bacterial Endotoxins. In European Pharmacopoeia, 3rd edition, Supplement, pp. 79–87. Strasbourg, France: Council of Europe.
173.
OutschoornA.S. (1982). The USP bacterial endotoxins test. Progress in Clinical and Biological Research93, 33–38.
174.
USP (2000). Pyrogen Test. In The United States Pharmacopoeia 24, pp. 1850–1851. Rockville, MD, USA: US Pharmacopoeial Convention.
175.
USP (2000). Bacterial Endotoxins Test. In The United States Pharmacopoeia24, pp. 1829–1831. Rockville, MD, USA: US Pharmacopoeial Convention.
176.
JP (2000). Bacterial Endotoxins Test. In The Japanese Pharmacopoeia 13, pp. 20–24. Shibuya, Shibuya-ku, Tokyo, Japan: The Society of Japanese Pharmacopoeia.
177.
JP (1996). Pyrogen Test. In The Japanese Pharmacopoeia 13, pp. 61. Shibuya, Shibuya-ku, Tokyo, Japan: The Society of Japanese Pharmacopoeia.
178.
Council of Europe (1994). Enquiry: monographs for antibiotics. PharmEuropa6, 316.
179.
Council of Europe (1998). Enquiry: monographs for biologicals. PharmEuropa10, 692.
180.
BallsM., & KarcherM. (1995). The validation of alternative test methods. ATLA23, 884–886.
181.
BallsM., BlaauboerB.J., FentemJ.H., BrunerL., CombesR.D., EkwallB., FielderR.J., GuillouzoA., LewisR.W., LovellD.P., ReinhardtC.A., RepettoG., SladowskiD., SpielmannH., & ZuccoF. (1995). Practical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM workshop 5. ATLA23, 129–147.
182.
CurrenR.D., SoutheeJ.A., SpielmannH., LiebschM., & FentemJ.H. (1995). The role of prevalidation in the development, validation and acceptance of alternative methods. ATLA23, 211–217.
183.
FentemJ.H., & BallsM. (1997). The ECVAM approach to validation. In Animal Alternatives, Welfare and Ethics (ed. van ZutphenL.F.M., & BallsM.), pp. 1083–1089. Amsterdam, The Netherlands: Elsevier.
184.
BallsM., & FentemJ.H. (1997). Progress toward the validation of alternative test. ATLA25, 33–43.
185.
Cooper-HannanR., HarbellJ.W., CoeckeS., BallsM., BoweG., CervinkaM., ClothierR., HermannF., KlahmL.K., de LangeJ., LiebschM., & VanparysP. (1999). The principles of Good Laboratory Practice: application to in vitro toxicology studies. The report and recommendations of ECVAM workshop 37. ATLA27, 539–577.
186.
ECVAM (1998). Statement on the scientific validity of the 3T3 NRU PT test (an in vitro test for phototoxic potential). ATLA26, 7–8.
187.
ECVAM (1998). Statement on the application of the 3T3 NRU PT test to UV filter chemicals. ATLA26, 385–386.
188.
ECVAM (1998). Statement on the scientific validity of the rat skin transcutaneous electrical resistence (TER) test (an in vitro test for skin corrosivity). ATLA26, 275–278.
189.
ECVAM (1998). Statement on the scientific validity of the EPISKIN™ test (an in vitro test for skin corrosivity). ATLA26, 278–280.
190.
ECVAM (1998). Statement on the scientific acceptability and practical availability of in vitro methods for the production of monoclonal antibodies. ATLA26, 383–385.
191.
BallsM., BlaauboerB.J., FentemJ.H., BrunerL., CombesR.D., EkwallB., FielderR.J., GuillouzoA., LewisR.W., LovellD.P., ReinhardtC.A., RepettoG., SladowskiD., SpielmannH., & ZuccoF. (1995). Practical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM workshop 5. ATLA23, 129–147
192.
BallsM., & KarcherM. (1995). The validation of alternative test methods. ATLA23, 884–886